查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827371

凝血和止血檢測市場（按最終用戶、技術、工作流程、產品和測試類型分類）—2025-2032 年全球預測

Coagulation & Hemostasis Testing Market by End User, Technology, Workflow, Products, Test Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，凝血和止血檢測市場將成長至 141.7 億美元，複合年成長率為 11.60%。

主要市場統計數據
基準年2024年 58.8億美元
預計2025年 65.6億美元
預測年份：2032年 141.7億美元
複合年成長率（%） 11.60%

了解不斷變化的臨床複雜性和診斷重點如何改變臨床、實驗室和研究環境中對凝血和止血測試的需求模式

凝血和止血檢測在現代患者照護中發揮核心作用，指導急性和慢性疾病的診斷途徑和治療決策。由於抗凝血治療的擴展、人口老化以及對個人化醫療日益成長的興趣，臨床複雜性日益增加，這推動了對準確、快速且可操作的凝血數據的需求。實驗室和即時檢驗 (POC) 環境面臨著提供可靠結果的挑戰，同時需要管理通量、試劑保存期限和成本壓力，而這些因素反過來又影響採購和工作流程策略。

醫院系統、診斷實驗室、診所和研究機構越來越需要將檢測數據與電子健康記錄和臨床決策支援整合。隨著診斷檢測方法的發展，相關人員必須在分析績效、營運效率和法規遵循之間取得平衡。本報告全面分析了當前的技術趨勢、臨床促進因素和營運挑戰，為醫療保健領導者、實驗室主任和商業團隊提供所需的洞見，幫助他們協調投資，從而改善臨床結果並增強營運韌性。

在整個分析過程中，我們強調實際影響而不是理論預測，目的是讓讀者清楚地了解不斷發展的診斷方式和醫療保健提供模式如何重塑不同臨床環境中的測試利用率、產品開發優先級和採購行為。

探索技術進步與變革性照護服務的融合，重新定義止血領域的檢測效能、臨床決策支援與診斷工作流程

隨著檢測技術和交付模式的進步與護理路徑的變化相融合，凝血和止血領域正在經歷變革。微射流和照護現場平台已超越概念驗證階段，在分散環境中實現了更高的分析準確性，並加速了從集中式實驗室轉向混合檢測網路的轉變。同時，免疫測量方法以及光學和電化學檢測方法的改進正在拓寬分析窗口，並提高D-二聚體和纖維蛋白原等關鍵分析物的靈敏度。

實驗室資訊系統與體外診斷資訊學解決方案的整合加快了決策週期，並改善了抗凝血治療管理。人工智慧和進階分析技術目前正應用於縱向凝血數據，從而實現模式識別，以支援風險分層和個人化治療調整。高通量分析儀的自動化減少了手動操作時間和差異性，而強大的試劑配方則提高了穩定性，並延長了各種儲存條件下的保存期限。

這些轉變加快了獲得結果的速度，增強了診斷信心，但也帶來了新的管治、互通性和採購挑戰。監管趨勢正在適應新的檢測化學方法和整合數位解決方案，製造商和臨床採用者正在推動更加重視驗證、臨床效用測試和上市後監測。這種力量的融合正在重新調整競爭優勢，使那些能夠將分析效能與系統級互通性和卓越服務相結合的組織能夠獲得競爭優勢。

評估累積關稅如何改變凝血和止血診斷價值鏈的供應連續性、籌資策略和採購決策

美國近期和擬議的關稅措施，為依賴全球供應鏈供應儀器、試劑和耗材的製造商、經銷商和臨床實驗室帶來了額外的複雜性。關稅主導的成本壓力往往會透過採購管道蔓延，影響定價策略，並提升合約重新談判和長期供應商承諾的重要性。醫療保健機構和診斷供應商正在積極重新評估其供應商組合，以尋找區域採購、替代物流路線和緊急庫存緩衝的機會，從而緩解潛在的價格波動和交貨日期的不確定性。

為了應對累積關稅的影響，一些製造商正在加速關鍵試劑和零件的近岸或國內生產，以降低跨境關稅和物流中斷的風險。這種轉變促使人們重新思考總到岸成本模型、前置作業時間假設以及本地製造能力的資本配置。實驗室和衛生系統正在透過增加諸如供應安全性、供應商多元化以及售後支援和維護服務的可用性等評估標準來適應變化。

長期影響包括採購框架的變化，優先考慮靈活性和韌性，而不是最低的前期成本。策略夥伴關係和庫存共用模式可以在關稅主導期間保持臨床的連續性。在企業平衡短期營運需求和確保持續獲得​​高品質血液凝固檢驗資源的策略目標時，法規合規性、品質保證和遷移生產線的驗證仍然是至關重要的考慮因素。

獲得可操作的細分情報，將最終用戶需求、檢測技術、工作流程偏好、產品系列和單一測試類型與可操作的商業化優先順序相結合

細分市場洞察揭示了終端用戶、技術、工作流程、產品和檢測類型之間獨特的採用趨勢和購買行為。診斷實驗室通常需要高通量分析儀、強大的試劑方案和全面的品質控制支援；醫院實驗室優先考慮快速週轉、與臨床系統的整合以及全天候服務；醫生辦公室優先考慮緊湊的即時診斷解決方案和易用性；而研究部門則重視檢測靈活性和新型生物標記的發現。每個終端使用者類別對服務模式、培訓和上市後支援都有獨特的要求，製造商必須透過量身定做的上市方案來滿足這些要求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 直介面服抗凝血劑監測對臨床實驗室工作流程的影響
  • 照護現場凝血分析儀與電子健康記錄系統整合
  • 開發高靈敏度 D-二聚體檢測方法以改善靜脈血栓栓塞症的診斷
  • 採用微流體和實驗室晶片技術進行快速床邊止血檢測
  • 人工智慧演算法在凝血數據解讀及決策支援的應用
  • 利用遺傳和生物標記見解擴展個人化凝血分析
  • 基於免疫檢測測定的抗血小板藥物監測的日益普及推動了市場的成長
  • 不斷變化的監管環境影響新型凝血診斷設備的採用
  • 遠端患者監護平台在慢性抗凝血管理中的作用
  • 基於奈米技術的感測器在超靈敏檢測凝血因子方面的進展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 凝血和止血檢測市場（按最終用戶）

  • 診斷實驗室
  • 醫院檢查室
  • 醫生診所
  • 研究機構

9. 凝血和止血檢測市場（按技術）

  • 電化學檢測
  • 免疫檢測
    • ELISA
    • 免疫比濁法
  • 微流體
  • 光學檢測

第 10 章凝血和止血測試市場（按工作流程）

  • 基於實驗室
  • 照護現場

第 11 章凝血和止血檢測市場（按產品）

  • 裝置
    • 凝血分析儀
    • 照護現場凝血儀
  • 試劑和耗材
    • 活化部分凝血酶原時間（APTT）試劑
    • D-二聚體試劑
    • 纖維蛋白原試劑
    • PT/INR試劑
  • 軟體和服務
    • IVD資訊學解決方案
    • 維護和支援

第12章凝血及止血檢驗市場（依檢驗類型）

  • 促凝血酶原時間（APTT）測試
  • D-二聚體檢測
  • 纖維蛋白原檢測
  • PT/INR檢測

第13章凝血和止血檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章凝血和止血檢測市場（按組）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。 凝血和止血檢測市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Danaher Corporation
    • Sysmex Corporation
    • Instrumentation Laboratory Company
    • Diagnostica Stago SA
    • Ortho Clinical Diagnostics, Inc.
    • bioMerieux SA
    • Helena Laboratories, LLC
Product Code: MRR-434CCDA04D1D

The Coagulation & Hemostasis Testing Market is projected to grow by USD 14.17 billion at a CAGR of 11.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.88 billion
Estimated Year [2025] USD 6.56 billion
Forecast Year [2032] USD 14.17 billion
CAGR (%) 11.60%

Understand how evolving clinical complexity and diagnostic priorities are reshaping coagulation and hemostasis testing demand patterns across clinical, laboratory, and research settings

Coagulation and hemostasis testing occupies a central role in modern patient care, informing diagnostic pathways and guiding therapeutic decisions across acute and chronic settings. Growing clinical complexity, driven by expanding anticoagulant therapies, aging populations, and an increased focus on personalized medicine, has elevated demand for accurate, rapid, and actionable coagulation data. Laboratories and point-of-care environments are under pressure to deliver reliable results while managing throughput, reagent shelf life, and cost pressures, which in turn shapes procurement and workflow strategies.

Across hospital systems, diagnostic laboratories, physician offices, and research institutions, the need to integrate test data with electronic health records and clinical decision support has intensified. As diagnostic assays evolve, stakeholders must balance analytical performance, operational efficiency, and regulatory compliance. This report synthesizes current technology trends, clinical drivers, and operational challenges to equip healthcare leaders, laboratory directors, and commercial teams with the insights needed to align investments with clinical outcomes and operational resilience.

Throughout the analysis, emphasis is placed on practical implications rather than theoretical projections. The intent is to provide readers with a clear understanding of how evolving diagnostic modalities and care delivery models are reshaping test utilization, product development priorities, and procurement behaviors across diverse clinical settings.

Explore the converging technological advances and care delivery transformations that are redefining testing performance, clinical decision support, and diagnostic workflows in hemostasis

The coagulation and hemostasis landscape is undergoing transformative shifts as advances in assay technology and delivery models converge with changing care pathways. Microfluidics and point-of-care platforms have matured beyond proof-of-concept, enabling higher analytical fidelity in decentralized settings and accelerating the transition from centralized laboratories to hybrid testing networks. Concurrently, immunoassay refinements and improvements in optical and electrochemical detection methods are extending analytical windows and enhancing sensitivity for critical analytes such as D-dimer and fibrinogen.

Digitalization is a second pivotal shift; integration of laboratory information systems with IVD informatics solutions drives faster decision cycles and improved stewardship of anticoagulant therapy. Artificial intelligence and advanced analytics are increasingly applied to longitudinal coagulation data, enabling pattern recognition that supports risk stratification and individualized treatment adjustments. Automation in high-throughput laboratory analyzers reduces hands-on time and variability, while robust reagent formulations improve stability and extend usable lifetimes across diverse storage conditions.

Taken together, these shifts reduce time-to-result and increase diagnostic confidence, but they also raise new governance, interoperability, and procurement questions. Regulatory pathways are adapting to novel assay chemistries and integrated digital solutions, prompting manufacturers and clinical adopters to emphasize validation, clinical utility studies, and post-market surveillance. These converging forces realign competitive advantages toward organizations that can pair analytical performance with systems-level interoperability and service excellence.

Assess how cumulative tariff measures are reshaping supply continuity, sourcing strategies, and procurement decision-making across the coagulation and hemostasis diagnostics value chain

Recent and proposed tariff measures in the United States have introduced an additional layer of complexity for manufacturers, distributors, and clinical laboratories that rely on global supply chains for instruments, reagents, and consumables. Tariff-driven cost pressures tend to propagate through procurement channels, influencing pricing strategies and raising the importance of contract renegotiation and long-term supplier commitments. Healthcare organizations and diagnostic suppliers are proactively reassessing supplier portfolios to identify opportunities for regional sourcing, alternative logistics routes, and contingency inventory buffers to mitigate potential price volatility and delivery uncertainty.

In response to cumulative tariff impacts, some manufacturers are accelerating near-shore or domestic production of critical reagents and components to reduce exposure to cross-border duties and logistics disruptions. This shift prompts reconsideration of total landed cost models, lead-time assumptions, and capital allocation for localized manufacturing capabilities. Laboratories and health systems are adapting by extending evaluation criteria to include supply stability, vendor diversification, and the availability of aftermarket support and maintenance services.

Longer-term implications include changes to procurement frameworks that prioritize flexibility and resilience over minimal upfront cost. Strategic partnerships and shared inventory models can sustain clinical continuity during periods of tariff-driven volatility. Regulatory compliance, quality assurance, and validation of relocated manufacturing lines remain essential considerations as organizations balance near-term operational needs with the strategic objective of securing stable access to high-quality coagulation testing resources.

Gain actionable segmentation intelligence that aligns end-user needs, assay technologies, workflow preferences, product portfolios, and discrete test types with practical commercialization priorities

Segment-focused insights reveal differentiated adoption dynamics and purchasing behaviors across end users, technologies, workflows, products, and test types. Based on end user, the diagnostic lab segment typically demands high-throughput analyzers and robust reagent programs with extensive QC support, hospital labs prioritize rapid turnaround, integration with clinical systems, and 24/7 serviceability, physician offices emphasize compact point-of-care solutions and ease of use, and research institutes focus on assay flexibility and novel biomarker exploration. Each end-user category imposes unique requirements for service models, training, and post-market support that manufacturers must address through tailored go-to-market approaches.

Based on technology, electrochemical detection offers advantages in miniaturization and energy efficiency that complement mobile and POC formats, while immunoassays remain a workhorse for many analytes with ELISA delivering high analytical precision and immunoturbidimetric methods providing automated throughput for routine testing. Microfluidics enables rapid assay kinetics and low sample volumes, supporting decentralized testing, and optical detection continues to underpin many high-sensitivity laboratory platforms. Understanding the trade-offs between sensitivity, throughput, and operational complexity is essential for matching technology to clinical use cases and site capabilities.

Based on workflow, laboratory-based settings emphasize batch processing, QC integration, and interoperability with laboratory information systems, whereas point-of-care workflows prioritize rapid, ergonomically designed instruments, minimal sample preparation, and clear clinician-facing decision support. Based on products, instruments encompass both coagulation analyzers designed for centralized labs and compact point-of-care coagulometers for bedside or clinic use; reagents and consumables include aPTT reagents, D-dimer reagents, fibrinogen reagents, and PT/INR reagents each with distinct stability and calibration needs; and software and services span IVD informatics solutions that enable result management and analytics alongside maintenance and support offerings that ensure uptime and regulatory compliance. Based on test type, aPTT, D-dimer, fibrinogen, and PT/INR tests each address discrete clinical questions from bleeding risk to thrombosis screening and perioperative management, influencing purchasing patterns, stocking priorities, and training needs across clinical sites.

These layered segmentation perspectives underscore the necessity of integrated commercial strategies that align product design, labeling, and post-sale support with the operational realities of the targeted end-user. Manufacturers that pair differentiated technology with service models attuned to workflow and test-type specifics will be better positioned to secure adoption and long-term partnerships.

Understand how regional regulatory environments, healthcare infrastructure maturity, and procurement practices drive differentiated adoption and commercialization pathways across global regions

Regional dynamics shape regulatory expectations, reimbursement mechanisms, and adoption velocity for coagulation and hemostasis testing. In the Americas, large integrated health systems and a significant focus on outpatient care drive demand for both high-throughput laboratory analyzers and scalable point-of-care solutions, with procurement decisions increasingly influenced by value-based care considerations and total cost of ownership analyses. Regulatory and payer environments encourage evidence generation that demonstrates clinical utility and cost-effectiveness, prompting manufacturers to support robust real-world evidence programs and partnerships with clinical leaders.

In Europe, the Middle East & Africa, regulatory harmonization across diverse jurisdictions and varied reimbursement frameworks create both opportunities and complexities for market entry. Many countries emphasize diagnostics stewardship and regional reference lab networks, which can accelerate adoption of standardized assays while also requiring manufacturers to adapt labeling and service footprints to local needs. Capacity constraints in some areas drive interest in portable, low-maintenance technologies and reagent stability tailored to variable supply chain conditions.

In Asia-Pacific, a combination of large population bases, rapid healthcare infrastructure development, and diverse public and private payer models has increased demand for scalable testing solutions. Market actors in this region often prioritize cost-effective, high-throughput reagents and versatile analyzers that can address heterogeneous clinical settings from tertiary hospitals to remote clinics. Regional manufacturing hubs and supply chain networks also influence procurement strategies, and partnerships with local distributors or contract manufacturers are common tactics to accelerate access and ensure compliance with local regulatory requirements.

Examine competitive strategies that combine analytical excellence, integrated services, and strategic partnerships to secure long-term adoption in coagulation and hemostasis testing

Company-level dynamics emphasize the interplay of product breadth, service capability, and strategic partnerships. Leading diagnostic firms that combine end-to-end solutions-spanning analyzers, reagent ecosystems, and informatics-tend to secure deeper integration within hospital laboratories due to the value derived from interoperability, consolidated vendor management, and predictable service contracts. Conversely, specialized reagent innovators and niche platform providers compete on assay performance, reagent stability, and targeted clinical evidence that validates clinical utility for specific test types.

Competitive differentiation increasingly relies on aftermarket services, including predictive maintenance, remote diagnostics, and flexible reagent supply models that accommodate consumption variability. Collaborations between instrument manufacturers and informatics providers are expanding the ability to offer decision-support tools that translate coagulation results into actionable clinical insights. Additionally, strategic alliances with contract manufacturers and logistics providers help companies mitigate tariff and supply-chain risks while preserving price competitiveness.

Mergers, acquisitions, and licensing arrangements remain important mechanisms for firms seeking to broaden portfolios, access new technologies, or enter regional markets with established distribution channels. Companies that invest in clinical validation, regulatory preparedness, and scalable manufacturing capacity are better positioned to respond to both clinical demand shifts and policy-driven disruptions. Ultimately, winning commercial approaches balance technological excellence with resilient service delivery and evidence-based value propositions.

Implement resilient sourcing, evidence-driven commercialization, and digital integration strategies to accelerate adoption and protect clinical continuity in evolving diagnostic environments

Industry leaders should prioritize resilience and clinical relevance when shaping near-term strategies. First, strengthening supply-chain diversity by qualifying secondary suppliers, exploring near-shore manufacturing, and establishing inventory buffers will reduce vulnerability to cross-border tariffs and logistics disruptions. Concurrently, firms should realign commercial models to emphasize total cost of ownership and outcome-linked value, enabling procurement stakeholders to evaluate offerings through a clinical and operational impact lens.

Investment in point-of-care and microfluidic platforms will address growing demand for decentralized testing, while simultaneous enhancement of IVD informatics capabilities will support clinical decision-making and interoperability with electronic health records. Companies should also invest in robust clinical validation programs that demonstrate real-world utility for key test types, enabling more persuasive engagement with payers and health systems. In parallel, flexible service models-such as pay-per-test reagent contracts or outcome-based maintenance agreements-can differentiate offerings and deepen customer relationships.

Operationally, organizations must streamline regulatory readiness and quality systems to expedite product introductions and adapt to shifting policy requirements. Sales and marketing teams should adopt consultative approaches that align technical advantages with specific end-user workflows and procurement criteria. Finally, leadership should foster collaborative partnerships with clinical networks and system integrators to co-develop protocols and evidence frameworks that accelerate adoption and improve patient outcomes.

A rigorous mixed-methods research approach combining practitioner interviews, technical review, and supply-chain analysis to produce validated, operationally focused diagnostic insights

The research underpinning this report combined qualitative and quantitative approaches designed to ensure rigor and practical relevance. Primary research included structured interviews with laboratory directors, hospital procurement leaders, clinical pathologists, and product managers, supplemented by technical briefings with assay developers and informatics specialists. These conversations provided context on workflow constraints, procurement priorities, and post-sale service expectations across a range of clinical settings.

Secondary research reviewed peer-reviewed literature, regulatory guidance documents, technology white papers, and product technical specifications to map technological capabilities and compliance requirements. Supply-chain analysis incorporated publicly available trade data and logistics studies to identify stress points and mitigation strategies. Data synthesis employed triangulation across sources to validate insights and highlight divergent perspectives where consensus was limited.

Throughout the methodology, ethical standards governed interview protocols and data handling, and limitations were documented where regional variability or emerging regulatory changes could alter operational assumptions. The resultant framework emphasizes actionable intelligence derived from practitioner experience, product-level analysis, and supply-chain scrutiny to inform strategic and operational decisions.

Synthesize how technological progress, clinical imperatives, and operational resilience converge to define the future trajectory of coagulation and hemostasis testing

Coagulation and hemostasis testing stands at an inflection point where technology, clinical need, and operational realities intersect. Advances in assay technologies and diagnostics informatics are enabling faster, more precise clinical decisions while decentralization trends require rethinking of workflows and support models. At the same time, external pressures such as trade policy and supply-chain complexity are prompting industry participants to reorient sourcing and manufacturing strategies in favor of resilience and proximity.

For stakeholders across clinical, commercial, and operational roles, the imperative is clear: align product innovation with demonstrable clinical value, ensure service and supply robustness, and leverage digital capabilities to translate results into actionable care pathways. Organizations that adopt integrated approaches-combining technological differentiation with evidence generation and flexible service models-are best positioned to navigate disruption and capture the clinical and operational benefits of evolving practice patterns.

Moving forward, sustained collaboration between diagnostic manufacturers, clinical leaders, and health systems will be essential to refine assay utility, streamline adoption, and preserve continuity of care under shifting policy and economic conditions. The pathway to durable impact lies in pragmatic deployment of innovation coupled with disciplined operational execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of direct oral anticoagulant monitoring on laboratory testing workflows
  • 5.2. Integration of point-of-care coagulation analyzers with electronic health record systems
  • 5.3. Development of high-sensitivity D-dimer assays for improved venous thromboembolism diagnostics
  • 5.4. Adoption of microfluidic and lab-on-a-chip technologies for rapid hemostasis testing at bedside
  • 5.5. Application of artificial intelligence algorithms in hemostasis data interpretation and decision support
  • 5.6. Expansion of personalized coagulation profiling using genetic and biomarker insights
  • 5.7. Market growth driven by increasing adoption of immunoassay-based antiplatelet drug monitoring
  • 5.8. Regulatory landscape evolution affecting adoption of novel coagulation diagnostic devices
  • 5.9. Role of remote patient monitoring platforms in chronic anticoagulation therapy management
  • 5.10. Advances in nanotechnology-enabled sensors for ultrasensitive detection of clotting factors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coagulation & Hemostasis Testing Market, by End User

  • 8.1. Diagnostic Labs
  • 8.2. Hospital Labs
  • 8.3. Physician Offices
  • 8.4. Research Institutes

9. Coagulation & Hemostasis Testing Market, by Technology

  • 9.1. Electrochemical Detection
  • 9.2. Immunoassays
    • 9.2.1. ELISA
    • 9.2.2. Immunoturbidimetric
  • 9.3. Microfluidics
  • 9.4. Optical Detection

10. Coagulation & Hemostasis Testing Market, by Workflow

  • 10.1. Laboratory Based
  • 10.2. Point Of Care

11. Coagulation & Hemostasis Testing Market, by Products

  • 11.1. Instruments
    • 11.1.1. Coagulation Analyzers
    • 11.1.2. Point-of-Care Coagulometers
  • 11.2. Reagents & Consumables
    • 11.2.1. aPTT Reagents
    • 11.2.2. D-Dimer Reagents
    • 11.2.3. Fibrinogen Reagents
    • 11.2.4. PT/INR Reagents
  • 11.3. Software & Services
    • 11.3.1. IVD Informatics Solutions
    • 11.3.2. Maintenance & Support

12. Coagulation & Hemostasis Testing Market, by Test Type

  • 12.1. aPTT Tests
  • 12.2. D-Dimer Tests
  • 12.3. Fibrinogen Tests
  • 12.4. PT/INR Tests

13. Coagulation & Hemostasis Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Coagulation & Hemostasis Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Coagulation & Hemostasis Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Abbott Laboratories
    • 16.3.4. Danaher Corporation
    • 16.3.5. Sysmex Corporation
    • 16.3.6. Instrumentation Laboratory Company
    • 16.3.7. Diagnostica Stago SA
    • 16.3.8. Ortho Clinical Diagnostics, Inc.
    • 16.3.9. bioMerieux SA
    • 16.3.10. Helena Laboratories, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. COAGULATION & HEMOSTASIS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. COAGULATION & HEMOSTASIS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COAGULATION & HEMOSTASIS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COAGULATION ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE COAGULOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IVD INFORMATICS SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY APTT TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PT/INR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY SOFTWARE